Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons
- 1 January 1992
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 66 (1) , 172-182
- https://doi.org/10.1128/jvi.66.1.172-182.1992
Abstract
The protection of individuals from human immunodeficiency virus type 1 (HIV-1) infection with an envelope subunit derived from a single isolate will require the presentation of conserved epitopes in gp120. The objective of the studies presented here was to test whether a native recombinant gp120 (rgp120) immunogen would elicit responses to conserved neutralization epitopes that are not present in a denatured recombinant gp120 antigen from the same virus isolate. In a large study of 51 baboons, we have generated heterologous neutralizing activity with native, glycosylated rgp120SF2 but not with denatured, nonglycosylated env 2-3SF2. After repeated exposure to rgp120SF2 formulated with one of several adjuvants, virus isolates from the United States, the Caribbean, and Africa were neutralized. The timing of the immunization regimen and the choice of adjuvant affected the virus neutralization titers both quantitatively and qualitatively. These results suggest that vaccination with native, glycosylated rgp120 from a single virus isolate, HIV-SF2, may elicit a protective immune response effective against geographically and sequentially distinct HIV-1 isolates.Keywords
This publication has 40 references indexed in Scilit:
- Cross-Neutralizing Antibodies in Rabbits Immunized with HIV-1 gp160 Purified from Simian Cells Infected with a Recombinant Vaccinia VirusAIDS Research and Human Retroviruses, 1991
- Sequence Analysis of the V3 Loop Regions of theenvGenes of Ugandan Human Immunodeficiency ProvirusesAIDS Research and Human Retroviruses, 1991
- Conserved Sequence and Structural Elements in the HIV-1 Principal Neutralizing DeterminantScience, 1990
- Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160Nature, 1990
- Predominance of HIV-1 serotype distinct from LAV-1/HTLV-IIIBThe Lancet, 1990
- Effect of Dose and Immunization Schedule on Immune Response of Baboons to Recombinant Glycoprotein 120 of HIV-1The Journal of Infectious Diseases, 1989
- Human immunodeficiency virus 1. Predominance of a group-specific neutralizing epitope that persists despite genetic variation.The Journal of Experimental Medicine, 1989
- A Major Neutralizing Domain Maps within the Carboxyl-terminal Half of the Cleaved Cytomegalovirus B GlycoproteinJournal of General Virology, 1989
- Temporal development of cross-neutralization between HTLV-III B and HTLV-III RF in experimentally infected chimpanzeesVaccine, 1988
- Neutralization of the AIDS Retrovirus by Antibodies to a Recombinant Envelope GlycoproteinScience, 1986